First-in-human study investigating the safety and immunogenicity of ISA's proprietary Amplivant adjuvant conjugated to human papillomavirus type 16 (HPV16) Synthetic Long Peptides (SLPs). SLPs
/PRNewswire/ ISA Pharmaceuticals B.V., a clinical stage biotech company developing immunotherapies to treat cancers and infectious diseases, today announces.
- Data published in the Journal of ImmunoTherapy of Cancer confirms efficacy of combination treatment (anti-PD1 + ISA101b) - Deep and durable responses have a profound positive effect
/PRNewswire/ ISA Pharmaceuticals B.V., a clinical stage biotech company developing immunotherapies to treat cancers and infectious diseases, today announces.
ISA Pharmaceuticals Receives Fast Track Designation for Lead Product ISA101b finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.